Molecularly-targeted therapy is for patients with specific mutations and generally after failure of immunotherapy, since these agents have a limited duration of activity. Efforts to discover the mechanisms of resistance to immunotherapy and molecularly-targeted therapy will inform new treatments and ...
A clinical trial can give you early access to a new drug or other treatment. By taking part in a study, you also help doctors discover new treatments or cures that could one day help other people with metastatic melanoma. Many clinical trials will pay for your: Tests Treatments Medical care...
The multiple cutaneous and subcutaneous metastases of melanoma are believed to be the result of intralymphatic spread of tumour cells. Therefore the longstanding complete remission is difficult to obtain and cures are very rare. The treatment modality which is the most appropriate if nodules are few...
Choice of therapy in the control arm of a clinical trial must be an established standard of care, with acceptable toxicity and proven survival benefit. Anti-PD-1 monotherapy has a proven survival benefit over previous treatments, without the additional toxicity burden of combination therapy. In bot...
Molecularly-targeted therapy is for patients with specific mutations and generally after failure of immunotherapy, since these agents have a limited duration of activity. Efforts to discover the mechanisms of resistance to immunotherapy and molecularly-targeted therapy will inform new treatments and ...
The therapeutic effects of traditional MM treatments are not ideal, primarily because they are mostly immuno-suppressive [16]. Surgical resection can impair the immunologic functions of lymphocytes and natural killer cell, which in turn leads to the spread or metastasize of tumor cells [17]. ...
Melanoma Institute Australia is the world’s leading centre for care, research, and education around melanoma. It regularly pioneers new treatments - efforts for which it has been recognised with multiple awards. It houses the world’s largest melanoma research database, as well as nearly 50,000...
Immune-based treatments for central nervous system gliomas have traditionally lagged behind those of more immunogenic tumors such as melanoma. The relative... RM Prins,SK Odesa,LM Liau - 《Cancer Research》 被引量: 193发表: 2004年 Induction of a Systemic Immune Response by a Polyvalent Melanoma...
Importantly, the majority of patients who are treated with high dose IL-2, biochemotherapy and/or anti-CTLA4 ultimately experience progression and few efficacious alternative treatments are currently available. We found that transient depletion of CD4+ and CD8+ T cells in melanoma patients via ...
Three serious AEs were related to study treatments. Two grade 4 AEs, and one grade 3 AE were recorded. During treatment with vemurafenib 960 mg b.i.d. + PEG-IFN-α-2b 1 µg/kg once weekly, 65.3% of the AEs observed were of mild severity, 28.6% moderate, and 4.1% ...